USANA HEALTH SCIENCES INC Earnings Per Share Disclosure
| Year Ended | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Net earnings attributable to USANA | $ | 10,760 | $ | 42,030 | $ | 63,788 | |||||||||||
| Weighted average common shares outstanding - basic | 18,535 | 19,103 | 19,250 | ||||||||||||||
| Dilutive effect of in-the-money equity awards | 39 | 59 | 95 | ||||||||||||||
| Weighted average common shares outstanding - diluted | 18,574 | 19,162 | 19,345 | ||||||||||||||
| Earnings per common share from net earnings attributable to USANA: | |||||||||||||||||
| Basic | $ | 0.58 | $ | 2.20 | $ | 3.31 | |||||||||||
| Diluted | $ | 0.58 | $ | 2.19 | $ | 3.30 | |||||||||||
| Anti-dilutive equity awards excluded from computation of diluted EPS attributable to USANA | 521 | 567 | 319 | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | Mar 16, 2026 | Showing above |
| 2024 | Mar 12, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 28, 2023 | |
| 2021 | Mar 2, 2021 | |
| 2019 | Feb 25, 2020 | |
| 2018 | Feb 26, 2019 | |
| 2017 | Feb 28, 2018 | |
| 2016 | Mar 1, 2017 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.